Abliva Toekomstige groei

Future criteriumcontroles 0/6

De winst van Abliva zal naar verwachting dalen met 17.6% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 137.1% per jaar. De winst per aandeel zal naar verwachting afnemen met 7.3% per jaar.

Belangrijke informatie

-17.6%

Groei van de winst

-7.3%

Groei van de winst per aandeel

Biotechs winstgroei	45.7%
Inkomstengroei	137.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	27 Aug 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

OM:ABLI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3	-161	-154	-153	1
12/31/2025	N/A	-141	-135	-134	1
12/31/2024	N/A	-119	-111	-110	1
6/30/2024	0	-102	-58	-57	N/A
3/31/2024	0	-98	-28	-27	N/A
12/31/2023	0	-96	-9	-8	N/A
9/30/2023	N/A	-88	-15	-15	N/A
6/30/2023	0	-80	-115	-114	N/A
3/31/2023	0	-79	-145	-144	N/A
12/31/2022	0	-85	-160	-160	N/A
9/30/2022	0	-105	-195	-194	N/A
6/30/2022	0	-114	-121	-120	N/A
3/31/2022	0	-124	-124	-123	N/A
12/31/2021	0	-123	-115	-114	N/A
9/30/2021	2	-100	-86	-84	N/A
6/30/2021	2	-75	-69	-68	N/A
3/31/2021	2	-65	-54	-53	N/A
12/31/2020	2	-60	-69	-68	N/A
9/30/2020	1	-74	-79	-77	N/A
6/30/2020	3	-79	-84	-82	N/A
3/31/2020	4	-80	-83	-80	N/A
12/31/2019	4	-77	-75	-72	N/A
9/30/2019	4	-65	-67	-63	N/A
6/30/2019	2	-64	-61	-57	N/A
3/31/2019	2	-69	-75	-72	N/A
12/31/2018	2	-68	-68	-64	N/A
9/30/2018	2	-68	-66	-62	N/A
6/30/2018	2	-66	-68	-64	N/A
3/31/2018	0	-63	N/A	-57	N/A
12/31/2017	0	-67	N/A	-58	N/A
9/30/2017	0	-66	N/A	-60	N/A
6/30/2017	0	-87	N/A	-55	N/A
3/31/2017	0	-76	N/A	-55	N/A
12/31/2016	0	-70	N/A	-57	N/A
9/30/2016	N/A	-63	N/A	-62	N/A
6/30/2016	N/A	-83	N/A	-66	N/A
3/31/2016	3	-87	N/A	-59	N/A
12/31/2015	3	-90	N/A	-67	N/A
9/30/2015	4	-100	N/A	-52	N/A
6/30/2015	11	-49	N/A	-50	N/A
3/31/2015	8	-47	N/A	-49	N/A
12/31/2014	8	-43	N/A	-44	N/A
9/30/2014	7	-35	N/A	-47	N/A
6/30/2014	1	-38	N/A	-41	N/A
3/31/2014	6	-27	N/A	-31	N/A
12/31/2013	7	-22	N/A	-19	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ABLI de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ABLI de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ABLI de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat ABLI volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat ABLI volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ABLI naar verwachting over 3 jaar hoog zal zijn

Abliva Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

New major risk - Shareholder dilution

New major risk - Financial position

Abliva AB (publ) Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

Abliva AB (Publ) Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease

New minor risk - Shareholder dilution

Abliva AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 46.093054 million.

Full year 2023 earnings released: kr0.09 loss per share (vs kr0.12 loss in FY 2022)

New minor risk - Share price stability

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Abliva AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

Abliva AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Abliva AB (publ) Achieves Important Milestone in the Ongoing FALCON Study

Abliva AB (publ), Annual General Meeting, May 23, 2024

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Chairman of the Board recently bought kr494k worth of stock

Abliva AB (Publ) Announces First Patient Dosed in the Falcon Study

Abliva AB (Publ) Announces Resignation of Edwin Moses as Director

Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333

No independent directors

Abliva AB (publ), Annual General Meeting, Apr 27, 2023

Abliva AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Director recently bought kr35m worth of stock

Abliva AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

No independent directors

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Full year 2021 earnings: EPS misses analyst expectations

US Food and Drug Administration Approves Abliva's Investigational New Drug (IND) Application for KL1333

Third quarter 2021 earnings released: kr0.086 loss per share (vs kr0.03 loss in 3Q 2020)

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Abliva Reports Positive Clinical Phase 1A/B Results for KL1333 Including Signs of Efficacy in PMD Patients

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Abliva Completes Phase Ia/Ib Study with KL1333

Full year 2020 earnings released: kr0.24 loss per share (vs kr0.45 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day low: kr0.74

Chief Executive Officer Erik Kinnmann has left the company

Abliva Announces CEO Changes, with Effect from February 3rd

New 90-day low: kr0.77

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Third quarter 2020 earnings released: kr0.03 loss per share

Abliva AB (publ) to Report Fiscal Year 2021 Results on Feb 22, 2022

New 90-day low: kr0.78

New 90-day low: kr0.91

Abliva AB Announces Resignation of Magnus Persson From Board of Directors

Earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven